New hope for Hard-to-Treat gut cancers: first human trial launched
NCT ID NCT05411133
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 32 times
Summary
This early study tested a new drug called Cabotamig (ARB202) in 33 adults with advanced gastrointestinal cancers (like stomach, liver, or bowel cancer) that had stopped responding to standard treatments. The drug works by targeting a marker called CDH17 on cancer cells and helping the immune system attack them. The main goals were to check safety and how the drug behaves in the body, and to see if it could shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Queen Mary Hospital
Hong Kong, Hong Kong
-
Southern Oncology Clinical Research Unit
Adelaide, Australia
-
St George Private Hospital
Sydney, Australia
Conditions
Explore the condition pages connected to this study.